Factors associated with the use of various medications amongst patients with severe coronary artery disease

Aim. To describe variations by age, sex, symptom severity and hospital regi on in the use of various medications amongst patients with stable angina pe ctoris who are candidates for coronary revascularization. Patients. Patients (n = 2030) with chronic stable angina pectoris participa ting in a national survey evaluating the appropriateness of the use of perc utaneous transluminal coronary angioplasty (PTCA) and coronary artery bypas s grafting (CABG). Methods. As part of a national study of the appropriateness of coronary rev ascularization, data were prospectively collected on patients referred for consideration of coronary revascularization to seven of the eight public Sw edish heart centres that performed approximately 92% of all bypass operatio ns in Sweden in 1994. Results. Amongst all patients 76% were treated with beta blockers, 41% with calcium antagonists and 71% with long-acting nitrates and 70% were treated with at least two of these three drugs. Eighty-two per cent of the patient s used aspirin and 14% lipid-lowering drugs. According to logistic regressi on analysis, with medication as the dependent variable and independent vari ables of age, sex, angina functional class, findings at exercise test, hist ory of various diseases and region in Sweden where the investigation took p lace, the most consistent factor explaining the use of various medications was found to be geographical region. A previous history of acute myocardial infarction (AMI) was also associated with the use of all drugs and age was associated with all with the exception of beta blockers. Sex was not an in dependent factor explaining the use of any of the drugs. Conclusion. In a national survey including patients with stable angina pect oris who are potential candidates for coronary revascularization, the most important predictor for the use of various medications was the geographical region in which the investigation took place.